Reirradiation for recurrent glioblastoma: the significance of the residual tumor volume.

Journal: Journal of neuro-oncology
Published Date:

Abstract

PURPOSE: Recurrent glioblastoma has a poor prognosis, and its optimal management remains unclear. Reirradiation (re-RT) is a promising treatment option, but long-term outcomes and optimal patient selection criteria are not well established.

Authors

  • Sina Mansoorian
    Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitaetsstraße 27, 91054, Erlangen, Germany.
  • Manuel Schmidt
    Department of Neuroradiology, University of Erlangen-Nuremberg, Schwabachanlage 6, 91054, Erlangen, Germany.
  • Thomas Weissmann
    Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Daniel Delev
    Neurosurgical Artificial Intelligence Laboratory Aachen (NAILA), RWTH Aachen University Hospital, Aachen, Germany.
  • Dieter Henrik Heiland
    Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. henrik.heiland@uk-erlangen.de.
  • Roland Coras
    Institute of Neuropathology, University Hospitals, Erlangen, Germany.
  • Jenny Stritzelberger
    Department of Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany.
  • Marc Saake
    Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Daniel Höfler
    Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsstraße 27, DE- 91054, Erlangen, Germany.
  • Philipp Schubert
    Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.
  • Charlotte Schmitter
    Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, 91054, Germany.
  • Sebastian Lettmaier
    Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitaetsstraße 27, 91054, Erlangen, Germany.
  • Irina Filimonova
    Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitaetsstraße 27, 91054, Erlangen, Germany.
  • Benjamin Frey
    Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen & Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Udo S Gaipl
    Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitaetsstraße 27, 91054, Erlangen, Germany.
  • Luitpold V Distel
    Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Sabine Semrau
    Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitaetsstraße 27, 91054, Erlangen, Germany.
  • Christoph Bert
    Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Chukwuka Eze
    Department of Radiation Oncology, LMU Hospital Department of Radiotherapy and Radiation Oncology, Marchioninistr. 15, 81377 Munich, Germany, Munich, BY, 81377, GERMANY.
  • Stephan Schönecker
    Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
  • Claus Belka
    Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
  • Ingmar Blumcke
    Institute of Neuropathology, University Hospitals, Erlangen, Germany.
  • Michael Uder
    Institute of Radiology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Oliver Schnell
    Division of Pediatric Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Arnd Dörfler
    Department of Neuroradiology, Universitätsklinikum Erlangen, FAU, Erlangen, Germany.
  • Rainer Fietkau
    Department of Radiation Oncology, Universitätsklinikum Erlangen & Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Florian Putz
    Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.